A blood vessel protein reduces mortality in infectious disease

A blood vessel protein reduces mortality in infectious disease

17/01/2023 Osaka University

Researchers led by Osaka University demonstrate the role of endothelial cell-specific protein Robo4 in mediating vascular permeability and reducing mortality in severe infection

Osaka, Japan – Pipes play an essential role in bringing water to the faucets in your home, but if one of those pipes springs a leak, damage can result. Similarly, the vascular system plays an essential role in carrying oxygen and nutrients throughout the body, but too much vascular permeability, or space between the cells lining the blood vessels, can have devastating results. Recently, researchers in Japan have shed new light on a key protein involved in vascular permeability and its impact on mortality in infectious disease.

In a new study published in PNAS, researchers led by Osaka University have demonstrated the potential of endothelial cell-specific protein Roundabout4 (Robo4) as a therapeutic target to reduce mortality resulting from severe infection. Robo4 is expressed by endothelial cells that line the blood vessels. These cells regulate vascular permeability and allow for the exchange of substances from the blood vessels into the surrounding tissue and vice versa.

During the body’s immune response, vascular permeability facilitates the movement of important immune cells and the elimination of dangerous pathogens. However, in severe immune responses, such as may occur in infectious diseases like COVID-19, an excessive increase in vascular permeability, known as vascular hyperpermeability, may lead to organ damage and death. Currently, no drugs directly suppress vascular hyperpermeability. Because Robo4 has been previously shown to play a role in vascular permeability, the Osaka University-led research team set out to explore Robo4 as a potential target to reduce vascular permeability in severe infection.

“To investigate the effects of Robo4 on vascular hyperpermeability, we generated an endothelial cell-specific mouse model of conditional Robo4 overexpression,” says lead author of the study Maaya Morita. “Upon exposing these mice to lipopolysaccharide (LPS), which induces a severe immune response, the mice exhibited decreased vascular permeability and increased rates of survival.”

The researchers screened a library of drugs using a mouse endothelial cell line to identify pathways that are involved in the regulation of Robo4 and found that two competitive SMAD signaling pathways appear to regulate Robo4 expression. When the researchers treated LPS-injected mice with a drug that inhibits ALK1-SMAD signaling, they observed increased Robo4 expression, decreased vascular permeability, and reduced mortality. A reduction in mortality was also observed in mice exposed to SARS-CoV-2, the virus that causes COVID-19.

“We were pleased to find that treatment with ALK1 inhibitor increases Robo4 expression and reduces mortality in mice under sepsis and SARS-CoV-2 conditions,” says senior author Yoshiaki Okada. “Increasing Robo4 expression may represent a strategy to reduce vascular permeability and alleviate severe infections.”

The research team’s findings may aid in the development of preventative or therapeutic drugs to reduce the mortality rate of severe infectious diseases, such as COVID-19.


The article, “Upregulation of Robo4 expression by SMAD signaling suppresses vascular
permeability and mortality in endotoxemia and COVID-19 models,” was published in PNAS at DOI: https://doi.org/10.1073/pnas.2213317120.
Title: Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models
Journal: Proceedings of the National Academy of Sciences
Authors: Maaya Morita, Aki Yoneda, Nagisa Tokunoh, Tatsumi Masaki, Keisuke Shirakura, Mayumi Kinoshita, Rina Hashimoto, Naoya Shigesada, Junya Takahashi, Masashi Tachibana, Shota Tanaka, Masanori Obana, Nobumasa Hino, Masahito Ikawa, Kazutake Tsujikawa, Chikako Ono, Yoshiharu Matsuura, Hiroyasu Kidoya, Nobuyuki Takakura, Yoshiaki Kubota, Takefumi Doi, Kazuo Takayama, Yasuo Yoshioka, Yasushi Fujio, Yoshiaki Okada
DOI: 10.1073/pnas.2213317120
Funded by:
Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Takeda Science Foundation
Japan Research Foundation for Clinical Pharmacology
Mochida Memorial Foundation for Medical and Pharmaceutical Research
Nippon Foundation–Osaka University Project for Infectious Disease Prevention.
Attached files
  • Fig. A vascular permeability inhibitor and its therapeutic effect on SARS-CoV-2 infection (CC BY-NC, Original data are from PNSA and modified by Yoshiaki Okada)
17/01/2023 Osaka University
Regions: Asia, Japan
Keywords: Health, Medical, Covid-19, Covid-19


For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2023 by AlphaGalileo Terms Of Use Privacy Statement